Cover Image

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma

Gene silencing of O6-methylguanine-DNA methyltransferase (MGMT) by promoter methylation improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft...

Full description

Saved in:
Bibliographic Details
Main Authors: Jakob, Jens (Author) , Hille, Maren (Author) , Sauer, Christian (Author) , Ströbel, Philipp (Author) , Wenz, Frederik (Author) , Hohenberger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 30 October 2012
In: Radiation oncology
Year: 2012, Volume: 7
ISSN:1748-717X
DOI:10.1186/1748-717X-7-180
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/1748-717X-7-180
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/1748-717X-7-180
Get full text
Author Notes:Jens Jakob, Maren Hille, Christian Sauer, Philipp Ströbel, Frederik Wenz and Peter Hohenberger
Description
Summary:Gene silencing of O6-methylguanine-DNA methyltransferase (MGMT) by promoter methylation improves the outcome of glioblastoma patients after combined therapy of alkylating chemotherapeutic agents and radiation. The purpose of this study was to assess the frequency of MGMT promoter methylation in soft tissue sarcoma to identify patients eligible for alkylating agent chemotherapy such as temozolomide.
Item Description:Published 30 October 2012
Gesehen am 06.07.2018
Physical Description:Online Resource
ISSN:1748-717X
DOI:10.1186/1748-717X-7-180

Similar Items